The management of hormone receptor-positive (HR+) HER2-negative metastatic breast cancer focuses on targeted therapies and systemic treatments. Endocrine therapy, such as aromatase inhibitors or selective estrogen receptor modulators (SERMs), is often the first line of treatment. In cases of disease progression, targeted agents like CDK4/6 inhibitors may be added to enhance treatment efficacy. Chemotherapy may be considered when hormonal therapies are no longer effective. Regular monitoring and personalized treatment plans are crucial to address the unique characteristics of each patient's cancer, aiming to improve quality of life and prolong survival. Multidisciplinary care, including palliative support, is essential for optimal management.